Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Financial performance is mixed with strong EBITDA growth but declining annual EBITDA margin. Concerns include rising expenses, unclear tariff impacts, and competitive pressures on semaglutide. Positive aspects are stable US price erosion and strong US business growth. Management's lack of clarity on tariffs and severance costs adds uncertainty. Overall, the mixed signals suggest a neutral stock price movement.
Key Financial Performance
Revenue Q4 FY 2025 $996 million, reflecting a year-over-year growth of 20% and a sequential increase of 2%. The growth was driven by the strategic acquisition of the consumer health care business in nicotine replacement therapy, which added INR597 crores in Q4.
Revenue Full Year FY 2025 $3.8 billion, representing a growth of 17%. This includes contributions from the acquired NRT business and a 12% growth excluding NRT.
Gross Margin Q4 FY 2025 55.6%, reflecting a year-over-year decline of 300 basis points due to reduced manufacturing overhead leverage and higher milestone income recognized in the comparative period.
Gross Margin Full Year FY 2025 58.5%, consistent with FY 2024.
SG&A Expenses Q4 FY 2025 $282 million, marking a year-over-year increase of 17% due to the recently acquired NRT business and higher logistics costs.
SG&A Expenses Full Year FY 2025 $1.1 billion, up by 22% year-over-year, driven by the NRT business and other commercial activities.
R&D Investment Q4 FY 2025 $85 million, representing a year-over-year increase of 6%.
R&D Investment Full Year FY 2025 $320 million, reflecting a year-over-year increase of 20%, focused on building a differentiated pipeline.
EBITDA Q4 FY 2025 $290 million, registering a year-over-year growth of 32% and an EBITDA margin of 29.1%, an increase of 267 basis points year-over-year.
EBITDA Full Year FY 2025 $1.1 billion, reflecting year-over-year growth of 11%, with an annual EBITDA margin of 20.3%, down from 29.7% in FY 2024.
Profit Before Tax Q4 FY 2025 $235 million, up 25% year-over-year.
Profit Before Tax Full Year FY 2025 $899 million, a year-over-year growth of 7%.
Profit After Tax Q4 FY 2025 $187 million, up 22% year-over-year.
Profit After Tax Full Year FY 2025 INR5,655 crores, reflecting year-over-year growth of 2%.
Earnings Per Share Q4 FY 2025 INR19.1.
Earnings Per Share Full Year FY 2025 INR68.1.
Operating Working Capital FY 2025 INR1,590 crores, a reduction of INR192 crores compared to December 31, 2024.
Capital Expenditure FY 2025 INR2,699 crores.
Free Cash Flow FY 2025 INR1,332 crores before acquisition-related payouts.
Net Cash Surplus FY 2025 INR2,454 crores.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: This quarter, we launched seven new products bringing the total for the fiscal year to 18.
New Product Launches in Europe: This quarter, we launched 10 new generic products in Europe, bringing the total for the fiscal year to €39 million.
New Products in Emerging Markets: During the quarter, we launched 26 new products across various emerging market countries, bringing the total for FY 2025 to 85 products.
Market Expansion in North America: Our North America Generic business generated revenue of $418 million for the quarter, reflecting a year-on-year growth of 7%.
Market Expansion in Europe: Our European Generics business reported revenues of €140 million for the quarter, reflecting a year-on-year growth of 142%.
Market Position in India: We have maintained our position as a 10 largest player in Indian Pharmaceutical Market, IPM, and have marginally outperformed the IPM.
Operational Efficiencies: We continue to maintain a disciplined cost structure while strategically allocating resources to strengthen existing business and expand into new growth segments.
R&D Investment: R&D expenditures for the quarter stood at INR726 crores, $85 million, representing a year-over-year increase of 6%.
Strategic Acquisition: The phase integration of our newly acquired nicotine replacement therapy NRT business is moving forward as planned.
Biosimilar Strategy: We secured exclusive commercialization rights for the daratumumab biosimilar candidate on Henlius in the United States and Europe.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: The North America Generic business experienced price erosion, which impacted revenue despite increased volume and successful new product launches.
Regulatory Issues: The API manufacturing facility in CTO2 received VAI status from the U.S. FDA following a successful GMP inspection, indicating ongoing regulatory scrutiny.
Supply Chain Challenges: Higher prices impacting logistics costs were noted, contributing to increased SG&A expenses.
Economic Factors: The emerging market generic business faced unfavorable foreign exchange conditions, which affected revenue performance.
Impairment Losses: An impairment loss of INR77 crores ($9 million) in Q4 and INR169 crores ($20 million) for the full year was reported, related to adverse market conditions affecting product-related intangibles.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Achieved record high revenue exceeding $3.8 billion for FY 2025, with a 17% growth year-over-year.
EBITDA: Crossed $1 billion threshold in EBITDA for the first time, with a margin of 28% for FY 2025.
Strategic Acquisitions: Acquired a consumer health care business in nicotine replacement therapy, contributing INR1,202 crores to FY 2025 revenue.
Biosimilars Strategy: Secured exclusive commercialization rights for daratumumab biosimilar in the U.S. and Europe, and signed agreements for other biosimilars.
R&D Investment: R&D expenditures for FY 2025 were INR2,738 crores, reflecting a 20% increase, focusing on differentiated pipeline.
Future Revenue Expectations: Expect strong momentum to continue into FY 2026, with ongoing growth in core businesses and new product launches.
EBITDA Margin Outlook: EBITDA margins expected to remain resilient, exceeding 29% for Q4 and over 28% for FY 2025.
Tax Rate Guidance: Expect effective tax rate for FY 2026 to be similar to the current fiscal year.
Capital Expenditure: Capital expenditure for FY 2025 was INR2,699 crores, with plans to maintain financial discipline for future growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payment: The Board has recommended a payment of dividend of INR8 per equity share of face value of INR1 each, equivalent to 18% of the face value for the year ended March 31, 2025.
Share Buyback Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is your sense on the extent of tariff or to what level the tariff could be implemented on generic? Could it be in the API? Could KSM be included?
A:I wish I knew how much tariff will come. We are preparing ourselves for the scenarios, and we're obviously watching carefully the information as it will come. At this stage, the main effort is to ensure sustainability of supply.
Q:What are the mitigation factors that we are looking in case tariff is implemented for generics?
A:We are working closely with our customers to see what is the need in terms of inventories and future product demand.
Q:Would customers be open to absorbing an impact of any potential tariffs?
A:My sense is nobody wants to absorb the tariff. There will be a certain adjustment period in which people will have to walk together to see what to do with it.
Q:How much flexibility do we have to actually reduce this cost once Revlimid goes away?
A:We will continue to have sales double-digit growth and EBITDA ROCE 25% or above.
Q:Would R&D and SG&A costs still be at similar levels?
A:Yes, R&D and SG&A will be in the similar zone.
Q:Can you provide more color on the gross margin changes?
A:There are one-off costs in this quarter that impacted the manufacturing overheads.
Q:Can you please quantify the severance cost one-time impact for this quarter?
A:We will not give right now, but it's not a very small amount.
Q:What is the update on our GLP-1 or generic Semaglutide product across various markets?
A:We are gearing up to launch it during the calendar 2026 in all the markets that the IP landscape will allow us to launch.
Q:What is the sizing of the generic semaglutide opportunity for us in markets such as Canada and Brazil?
A:Canada is one of the markets that will open early, and the market price is around $1.8 billion.
Q:What is the U.S. business price erosion for the year?
A:The price erosion is very stable.
Q:How has the U.S. business performed for the year?
A:The U.S. business grew very nicely.
Q:What is the expected distribution of Revlimid sales over the next few quarters?
A:Likely that we will stop a few months before January to avoid price shelf adjustments.
Q:Is there significant price erosion in Revlimid compared to 6 months back?
A:Yes, there is a price erosion.
Q:What is the CapEx for this year and next year?
A:Major CapEx are going in two fronts: peptides and biosimilar facilities.
Q:What is the growth outlook for the India business?
A:We are planning to grow, and most of our growth will be inorganic.
Q:What is your take on the recent updates from the U.S. regarding regulatory concessions?
A:All of our facilities are ready for unannounced inspections.
Q:What is the visibility on R&D spend and pipeline buildup?
A:R&D investments have been increasing in biosimilars and generics.
Q:What is the competitive landscape for semaglutide in the U.S.?
A:We believe that the landscape of semaglutide will be very competitive.
Q:Review of Unclear Management Responses
A:Management avoided quantifying the severance cost one-time impact for this quarter, stating it is not a very small amount but did not provide specific figures. Additionally, they did not provide a clear answer on the extent of tariff implementation on generics, indicating uncertainty about future policies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abdulkader Puranwala
Capital
ETR reversal
FCTR
FY INR
Global Generics
Laboratories Limited
NRT
PBT
Periwal
Post
RD investment
SGA INR
amount
balance
contract
crore INR
crore acquisition
crore margin
decline basis
equity
exchange gain
expenditure INR
face value
income crore
investment RD
loss
margin FY
margin Global
participation
point decline
product intangible
production rate
provision
rate INR
reversal tax
tax asset
RDY Transcript
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A session reveal strong financial performance, product development, and market expansion strategies. Despite some challenges, such as lower gross margins and the wind-down of CAR-T investments, the company's optimistic guidance, new product launches, and market share gains indicate positive sentiment. The focus on emerging markets and sustainability goals further supports a positive outlook. The Q&A insights align with the earnings call, reinforcing the positive sentiment, especially with the expected growth in biosimilars and semaglutide. Therefore, the stock price is likely to experience a positive movement of 2% to 8%.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Positive1-21
The earnings call highlights strong revenue growth, successful product launches, and strategic collaborations, particularly in the Indian market. Despite a decline in PAT, the company maintains a robust cash position and expects sustainable growth. The Q&A reveals optimism about innovative products and market expansion, though there are some uncertainties in biosimilar timelines. Overall, the positive developments, particularly in India, and optimistic guidance outweigh the negatives, suggesting a positive stock price movement.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Unknown10-24
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Unknown5-9
Financial performance is mixed with strong EBITDA growth but declining annual EBITDA margin. Concerns include rising expenses, unclear tariff impacts, and competitive pressures on semaglutide. Positive aspects are stable US price erosion and strong US business growth. Management's lack of clarity on tariffs and severance costs adds uncertainty. Overall, the mixed signals suggest a neutral stock price movement.
RDY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
